2023-08-02 17:41:05 ET
- Outset Medical press release ( NASDAQ: OM ): Q2 Non-GAAP EPS of -$0.69 beats by $0.04 .
- Revenue of $36M (+43.4% Y/Y) beats by $1.21M .
-
Total cash, including restricted cash, cash equivalents and short-term investments, was $226.1 million as of June 30, 2023.
-
Full Year 2023 Financial Guidance
Outset reiterated its 2023 revenue guidance range of $144 million to $150 million vs. consensus of $147.35M, and now expects to be at the low end of this range as a result of the shipment pause for TabloCart with Prefiltration. The Company reaffirmed its gross margin guidance for the year to be in the low-20% range, exiting the fourth quarter in the mid-20% range.
For further details see:
Outset Medical beats Q2 top and bottom line estimates; reaffirms FY23 outlook